Single ascending dose and multiple ascending dose study of M132101 in healthy subjects.

A Phase 1,randomized,placebo-controlled,double-blind, single ascending dose and multiple ascending dose study of M132101 in healthy subjects.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2071230113

Enrollment

Registered

2024-02-08

Start date

2024-03-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infantile hemangioma

Interventions

M132101 or placebo will be topically applied once or twice a day for 7 days

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Males who are 18 to 44 years of age at the time of informed consent

Exclusion criteria

Exclusion criteria: (1)Individuals with a history or complications with liver, kidney, or heart disease, etc. considered inappropriate for participation in the clinical study (2)Individuals with abnormal findings (eczema/dermatitis, pigment abnormalities, inflammation due to sunburn, wounds, scars, skin infections, etc.) at the administration site. (3)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator

Design outcomes

Primary

Measure	Time frame
Tolerability, Safety, PK	—

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026